Laia Fernández-Barat1, Miquel Ferrer2, Francesca De Rosa3, Albert Gabarrús1, Mariano Esperatti4, Silvia Terraneo5, Mariano Rinaudo6, Gianluigi Li Bassi6, Antoni Torres6. 1. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro de Investigación Biomedica En Red-Enfermedades Respiratorias (CibeRes, CB06/06/0028), Spain. 2. Department of Pneumology, Respiratory Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro de Investigación Biomedica En Red-Enfermedades Respiratorias (CibeRes, CB06/06/0028), Spain. Electronic address: miferrer@clinic.ub.es. 3. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Dipartmento di Anestesia e Rianimazione, Università degli studi di Milano, Milan, Italy. 4. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain. 5. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Respiratory Unit, San Paolo Hospital, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy. 6. Department of Pneumology, Respiratory Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Centro de Investigación Biomedica En Red-Enfermedades Respiratorias (CibeRes, CB06/06/0028), Spain.
Abstract
OBJECTIVE: Pseudomonas aeruginosa often presents multi-drug resistance (MDR) in intensive care unit (ICU)-acquired pneumonia (ICUAP), possibly resulting in inappropriate empiric treatment and worse outcomes. We aimed to identify patients with ICUAP at risk for these pathogens in order to improve treatment selection and outcomes. METHODS: We prospectively assessed 222 consecutive immunocompetent ICUAP patients confirmed microbiologically. We determined the characteristics, risk factors, systemic inflammatory response and outcomes of P. aeruginosa pneumonia (Pa-ICUAP), compared to other aetiologies. We also compared patients with MDR vs. non-MDR Pa-ICUAP. RESULTS: Pseudomonas aeruginosa was the most frequent aetiology (64, 29%); 22 (34%) cases had MDR. Independent predictors for Pa-ICUAP were prior airway colonization by P. aeruginosa, previous antibiotic treatment, solid cancer and shock; alcohol abuse and pleural effusion were independently associated to lower risk for Pa-ICUAP. Chronic liver disease independently predicted MDR among Pa-ICUAP. The inflammatory biomarkers were similar between all groups. Patients with Pa-ICUAP had lower unadjusted 90-day survival (p = 0.049). However, the 90-day survival adjusted for confounding factors using a propensity score did not differ between all groups. CONCLUSION: Pseudomonas aeruginosa remains the most frequent aetiology of ICUAP, with high prevalence of MDR. These risk factors should be taken into account to avoid inappropriate empiric antibiotics for Pa-ICUAP. Pseudomonas aeruginosa, regardless multidrug resistance, was not associated with different propensity-adjusted survival.
OBJECTIVE:Pseudomonas aeruginosa often presents multi-drug resistance (MDR) in intensive care unit (ICU)-acquired pneumonia (ICUAP), possibly resulting in inappropriate empiric treatment and worse outcomes. We aimed to identify patients with ICUAP at risk for these pathogens in order to improve treatment selection and outcomes. METHODS: We prospectively assessed 222 consecutive immunocompetent ICUAP patients confirmed microbiologically. We determined the characteristics, risk factors, systemic inflammatory response and outcomes of P. aeruginosa pneumonia (Pa-ICUAP), compared to other aetiologies. We also compared patients with MDR vs. non-MDR Pa-ICUAP. RESULTS:Pseudomonas aeruginosa was the most frequent aetiology (64, 29%); 22 (34%) cases had MDR. Independent predictors for Pa-ICUAP were prior airway colonization by P. aeruginosa, previous antibiotic treatment, solid cancer and shock; alcohol abuse and pleural effusion were independently associated to lower risk for Pa-ICUAP. Chronic liver disease independently predicted MDR among Pa-ICUAP. The inflammatory biomarkers were similar between all groups. Patients with Pa-ICUAP had lower unadjusted 90-day survival (p = 0.049). However, the 90-day survival adjusted for confounding factors using a propensity score did not differ between all groups. CONCLUSION:Pseudomonas aeruginosa remains the most frequent aetiology of ICUAP, with high prevalence of MDR. These risk factors should be taken into account to avoid inappropriate empiric antibiotics for Pa-ICUAP. Pseudomonas aeruginosa, regardless multidrug resistance, was not associated with different propensity-adjusted survival.
Authors: Sebastián A Riquelme; Kalle Liimatta; Tania Wong Fok Lung; Blanche Fields; Danielle Ahn; David Chen; Carmen Lozano; Yolanda Sáenz; Anne-Catrin Uhlemann; Barbara C Kahl; Clemente J Britto; Emily DiMango; Alice Prince Journal: Cell Metab Date: 2020-05-18 Impact factor: 27.287
Authors: B Borgatta; S Gattarello; C A Mazo; A T Imbiscuso; M N Larrosa; M Lujàn; J Rello Journal: Eur J Clin Microbiol Infect Dis Date: 2017-06-17 Impact factor: 3.267
Authors: Maja K von Cube; Jean-Francois Timsit; Harriet Sommer; Michael Darmon; Carole Schwebel; Sebastien Bailly; Bertrand Souweine; Martin Wolkewitz Journal: Intensive Care Med Date: 2018-03-16 Impact factor: 17.440
Authors: Sadeep Shrestha; Rachael A Lee; Adeniyi J Idigo; J Michael Wells; Matthew L Brown; Howard W Wiener; Russell L Griffin; Gary Cutter Journal: Antimicrob Resist Infect Control Date: 2022-07-14 Impact factor: 6.454
Authors: Ghady Haidar; Nathan J Philips; Ryan K Shields; Daniel Snyder; Shaoji Cheng; Brian A Potoski; Yohei Doi; Binghua Hao; Ellen G Press; Vaughn S Cooper; Cornelius J Clancy; M Hong Nguyen Journal: Clin Infect Dis Date: 2017-07-01 Impact factor: 9.079
Authors: Fleur P Paling; Martin Wolkewitz; Pieter Depuydt; Liesbet de Bus; Frangiscos Sifakis; Marc J M Bonten; Jan A J W Kluytmans Journal: Antimicrob Resist Infect Control Date: 2017-04-20 Impact factor: 4.887